AAPL 221.875 -3.5242% MSFT 427.22 -0.4219% NVDA 139.85 1.554% GOOGL 199.3225 1.6952% GOOG 201.35 1.9236% AMZN 228.7043 1.2235% META 617.385 0.7531% AVGO 239.5299 0.8802% TSLA 413.825 -2.9719% TSM 213.7392 1.0587% LLY 735.7301 1.3793% V 322.15 0.7916% JPM 261.25 0.8065% UNH 520.02 2.0127% NVO 80.28 2.0206% WMT 93.245 1.4194% LVMUY 145.13 2.1467% XOM 111.61 -0.6321% LVMHF 725.1 1.976% MA 529.315 0.8796%
AAPL 221.875 -3.5242% MSFT 427.22 -0.4219% NVDA 139.85 1.554% GOOGL 199.3225 1.6952% GOOG 201.35 1.9236% AMZN 228.7043 1.2235% META 617.385 0.7531% AVGO 239.5299 0.8802% TSLA 413.825 -2.9719% TSM 213.7392 1.0587% LLY 735.7301 1.3793% V 322.15 0.7916% JPM 261.25 0.8065% UNH 520.02 2.0127% NVO 80.28 2.0206% WMT 93.245 1.4194% LVMUY 145.13 2.1467% XOM 111.61 -0.6321% LVMHF 725.1 1.976% MA 529.315 0.8796%

Summit Therapeutics PLC

Healthcare US SMMT

20.77USD
1.74(9.14%)

Last update at 2025-01-21T14:52:00Z

Day Range

19.2920.61
LowHigh

52 Week Range

1.525.39
LowHigh

Fundamentals

  • Previous Close 19.03
  • Market Cap1832.17M
  • Volume446856
  • P/E Ratio6.87
  • Dividend Yield-%
  • EBITDA-114.75000M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.70M
  • Diluted EPS TTM0.38

Financials

Income Statement

2019-01-312020-01-312021-01-312022-01-312023-01-31-80M-60M-40M-20M0M20M40M
Total Revenue
Net Income

Balancesheet

2020-01-312021-01-312022-01-312023-01-312024-01-310M50M100M150M200M250M300M350M400M450M500M550M600M650M
Total Assets
Total Liabilities

Change in Cash

2019-01-312020-01-312021-01-312022-01-312023-01-310M50M100M150M200M250M300M350M400M450M500M550M

Total Operating Cash

2019-01-312020-01-312021-01-312022-01-312023-01-31-75M-70M-65M-60M-55M-50M-45M-40M-35M-30M-25M

Dividends Paid

2019-01-312020-01-312021-01-312022-01-312023-01-310M
Breakdown 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Type yearly yearly yearly yearly yearly
Date 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Income before tax -78.78200M -88.60200M -52.91000M 4.99M 6.60M
Minority interest - - - - 0.00000M
Net income -74.38100M -86.14700M -52.69700M 4.99M 9.87M
Selling general administrative 26.70M 23.61M 19.23M - 16.19M
Selling and marketing expenses - - - - -
Gross profit 0.70M 1.81M 0.86M 43.01M 56.39M
Reconciled depreciation 2.51M 2.46M 2.00M - 1.49M
Ebit -72.08900M -88.64100M -53.19300M -25.55600M 12.38M
Ebitda -60.80300M -86.18600M -51.47500M 15.16M 13.87M
Depreciation and amortization 11.29M 2.46M 1.72M 0.52M 1.49M
Non operating income net other - - - - 0.00000M
Operating income -72.08900M -86.18600M -53.19300M 15.16M 12.38M
Other operating expenses 64.28M 88.00M 53.19M -39.18200M 47.69M
Interest expense 4.40M 0.28M 0.26M 0.00000M 0.56M
Tax provision - 0.00000M -0.21300M - -3.27366M
Interest income - 0.00000M 0.00400M - 0.00525M
Net interest income -4.40100M -0.28100M -0.25100M - 3.10M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense -4.40100M -2.45500M -0.21300M -3.84436M -3.27366M
Total revenue 0.70M 1.81M 0.86M 43.01M 56.41M
Total operating expenses 64.28M 88.00M 53.19M -39.18200M 47.69M
Cost of revenue - - - - 0.02M
Total other income expense net -6.69300M -2.41600M 0.28M -10.16200M -5.78267M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -78.78200M -88.60200M -52.69700M - 9.87M
Net income applicable to common shares -78.78200M -88.60200M -52.69700M -24.03491M 7.53M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2024-01-31 2023-01-31 2022-01-31 2021-01-31 2020-01-31
Type yearly yearly yearly yearly yearly
Date 2024-01-31 2023-01-31 2022-01-31 2021-01-31 2020-01-31
Total assets 202.95M 664.17M 113.37M 102.50M 24.44M
Intangible assets - - 10.40M 11.52M 10.60M
Earning assets - - - - -
Other current assets 0.18M 0.49M 1.20M 1.52M 5.80M
Total liab 125.26M 537.51M 30.09M 23.05M -18.09800M
Total stockholder equity 77.69M 126.65M 83.28M 79.45M 42.54M
Deferred long term liab - - - - -
Other current liab 0.72M 16.97M 12.22M 4.99M 1.49M
Common stock 7.02M 2.11M 0.98M 0.83M 3.36M
Capital stock 7.02M 2.11M 0.98M 0.83M -
Retained earnings -993.25800M -378.33000M -299.54800M -214.74000M -97.61900M
Other liab - 1.43M 2.78M 3.08M 3.98M
Good will 1.89M 1.80M 2.01M 2.03M 1.81M
Other assets - 0.58M 25.52M - -16.37700M
Cash 71.42M 348.61M 71.79M 66.42M 26.86M
Cash and equivalents - - - - -
Total current liabilities 20.41M 38.78M 25.62M 19.89M -1.83600M
Current deferred revenue 14.21M - 7.94M 8.37M -0.83100M
Net debt 34.67M 170.16M -69.00900M -65.95200M -27.86300M
Short term debt 2.81M 21.46M 1.09M 0.39M -1.00500M
Short long term debt - 19.77M - - -
Short long term debt total 106.10M 518.76M 2.78M 0.47M -1.00500M
Other stockholder equity 1066.38M 504.77M 384.05M 293.37M 42.54M
Property plant equipment - 5.08M 3.48M 1.28M 1.17M
Total current assets 189.71M 656.71M 97.31M 66.42M 26.86M
Long term investments - - - - -
Net tangible assets - 124.86M 70.88M 23.43M 47.46M
Short term investments 114.82M - - - -
Net receivables 0.85M 6.12M 17.16M 10.19M 5.13M
Long term debt 100.00M 494.54M - - -
Inventory 2.44M 301.50M 7.16M -11.71000M -
Accounts payable 2.67M 0.35M 4.37M 6.14M 3.39M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -2.44800M -1.89300M -2.19700M -3.79400M -
Additional paid in capital - - - - -
Common stock total equity - - - 0.83M -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 5.28M 0.58M 0.17M 21.26M -
Deferred long term asset charges - - - - -
Non current assets total 13.24M 7.46M 16.06M 36.08M 13.96M
Capital lease obligations 6.10M 4.45M 2.78M 0.47M -
Long term debt total - - - - -
Breakdown 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Type yearly yearly yearly yearly yearly
Date 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Investments -0.62400M -0.30600M -0.42100M - -0.41052M
Change to liabilities -11.41000M -2.52400M 7.01M -4.03636M -36.80500M
Total cashflows from investing activities -0.62400M -0.30600M -0.42100M -0.28691M -0.31300M
Net borrowings 520.00M 520.00M 520.00M -0.35782M -0.28100M
Total cash from financing activities 620.24M 77.92M 50.55M 33.11M 43.85M
Change to operating activities 19.05M 3.60M -6.60700M 3.70M -3.41700M
Net income -78.78200M -88.60200M -52.69700M -25.55600M 6.60M
Change in cash 576.82M 5.37M 2.58M 6.76M 8.86M
Begin period cash flow 71.79M 66.42M 63.84M 20.10M 26.37M
End period cash flow 648.61M 71.79M 66.42M 26.86M 35.23M
Total cash from operating activities -41.58200M -72.58700M -48.11100M -26.66300M -35.14329M
Issuance of capital stock 100.00M 75.00M 50.00M - 45.44M
Depreciation 2.51M 2.46M 2.00M 1.47M 1.49M
Other cashflows from investing activities - - -0.42100M 0.00436M 0.00400M
Dividends paid - - - - 0.00000M
Change to inventory - 3.60M -6.60700M - 0.00000M
Change to account receivables 0.97M -1.13800M 0.21M 4.66M -25.33687M
Sale purchase of stock - - - - 0.00000M
Other cashflows from financing activities 545.24M 112.92M 0.55M 33.11M -1.58830M
Change to netincome 26.07M 13.63M 4.59M 4.49M 3.56M
Capital expenditures 0.62M 0.31M 0.42M 0.12M 0.16M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital 8.62M -0.06700M 0.62M 4.37M -51.18106M
Stock based compensation 11.95M 12.80M 1.77M - 6.22M
Other non cash items 14.12M 0.50M -0.38500M -28.13600M 1.73M
Free cash flow -42.20600M -72.89300M -48.53200M -26.78200M -35.30723M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SMMT
Summit Therapeutics PLC
1.74 9.14% 20.77 6.87 - 753.90 33.10 6425.28 -4.1776
NVO
Novo Nordisk A/S
1.59 2.02% 80.28 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S
- -% 78.60 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
3.93 0.93% 425.93 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc
3.68 0.54% 685.26 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

Profile

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Summit Therapeutics PLC

601 Brickell Key Drive, Miami, FL, United States, 33131

Key Executives

Name Title Year Born
Mr. Robert W. Duggan CEO & Exec. Chairman 1944
Dr. Mahkam Zanganeh D.D.S., M.B.A., MBA Co-CEO, Pres & Director 1970
Dr. Urte Gayko Ph.D. Head of Regulatory Affairs, Quality Assurance & Safety and Director 1971
Prof. Dame Kay Davies DBE, FRS CBE Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor 1951
Mr. Ankur Dhingra Chief Financial Officer 1976
Ms. Michelle Avery Director of Investor Relations NA
Dr. Elaine Carla Stracker J.D., Ph.D. Head of Compliance? & Gen. Counsel 1961
Mr. Campbell Hair Head of HR? NA
Dr. Anne Heatherington Head of Clinical Devel. and Quantitative Sciences NA
Ms. Divya Chari Head of Global Clinical Operations 1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.